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ABSTRACT
Objective: Apoptosis is an important cellular process that causes the death of damaged cells. Its malfunction can lead to cancer development and 
poor response to conventional chemotherapy. Cellular proteins from the B-cell lymphoma 2 (BCL-2) family are crucial for apoptosis. Breast cancer is 
the most commonly diagnosed cancer among women worldwide. The aim of this work was to design using in silico docking antimycin A3, antimycin 
analogs, and its aromatic segments as inhibitors of Bcl-xl and Mcl-1.
Methods: In silico molecular docking approach has been utilized to find the potential anticancer from antimycin A3 analogs and its aromatic 
segments. Antimycin A3 analogs and its aromatic segments were modeled into three-dimensional (3D) structures using Marvin Sketch. Based on 
Protein Data Bank, 3ZLN for Bcl-xl, and 5IEZ for Mcl-1 were selected as apoptosis protein marker from BCL-2 family. Geometry optimization and 
minimization of energy 3D structure of antimycin A3 analogs and segments (ligands) using the AutoDock software. Docking process and amino 
acid residue analysis were executed using AutoDock software. The best docking score was shown by the lowest binding energy and also checked 
with Lipinski rule of five.
Results: In silico molecular docking showed antimycin A3 analogs, amide 5 and aromatic segment 14 have the best interaction and activity for Bcl-xl 
receptor inhibition. Moreover, amide 5 and segment 15 showed the best interaction and activity for Mcl-1 receptor inhibition.
Conclusion: Our results clearly demonstrate that amide 5, segment 14, and segment 15 of antimycin A3 analog have a strong inhibitory activity against 
Bcl-xl and Mcl-1, and should be further developed as a promising candidate for the new anti-apoptosis agents.
Keywords: Molecular docking, Antimycin A3 analog, Apoptosis, Bcl-xl, Mcl-1, Breast cancer.
INTRODUCTION
Apoptosis is a key for a cellular process that causes the death of 
damaged cells [1]. Malfunction of apoptosis can trigger to cancer 
development and poor response to conventional chemotherapy [2]. 
Cellular proteins from the B-cell lymphoma 2 (BCL-2) family are 
important for apoptosis [3,4]. Understanding their interactions is vital 
for anticancer drug design [5]. Proteins from the BCL-2 family can 
be either was (pro-apoptotic) or prosurvival (anti-apoptotic). Anti-
apoptotic proteins such as BCL-2, BCL-xl, and MCL-1, share homology 
in three to four conserved BH peptide domains, namely, BH1, BH2, BH3, 
and BH4 [6,7]. Pro-apoptotic proteins such as BAX, BAK, BIM, BAD, and 
BID, share homology only in the BH3 domain [8].
The BH3 region is responsible for mediating the interactions with 
anti-apoptotic proteins and is related to the ability of a protein to 
promote programed cell death [9]. The structures of BCL-2 and 
BCL-xl are composed of eight α-helices with a hydrophobic groove 
on the protein surface containing all the four (BH1, BH2, BH3, 
and BH4) conserved domains [10,11]. MCL-1 shows structural 
similarity with BCL-2 and BCL-xl except for the absence of BH4 
domain at the N-terminal [11]. After receiving the appropriate 
signals, pro-apoptotic proteins bind to anti-apoptotic proteins via 
BH3 domains on their surfaces. When cytochrome C is released from 
the mitochondrial inner membrane space, the apoptosis process 
is initiated [12]. Overexpression of anti-apoptotic BCL-2 family 
proteins prevents the release of cytochrome C from mitochondria 
and is responsible for many types of human cancers such as breast 
and prostate cancer [13,14].
Breast cancer is the most commonly diagnosed cancer among women 
worldwide. Approximately 30% of the women diagnosed with the 
early-stage disease in turn progress to metastatic breast cancer, 
for which treatment with anti-breast cancer therapeutic agents is 
needed. Although many current anti-breast cancer therapies can 
alter tumor growth, in most cases the effect is not long lasting, and 
commonly develop resistance against anticancer agents used which 
causes around 50% of all treated patients will relapse [15-17]. This 
fact indicated that the search for new agents which more effective, 
safe, and potentially extend the survival of breast cancer patients are 
needed.
Antimycin A3, a nine-membered dilactone which isolated from 
Streptomyces sp., is an active agent that inhibits the electron transfer 
activity of ubiquinol-cytochrome C oxidoreductase and prevents the 
growth of human cancer cells [15]. Antimycin A3 was also found to 
induce apoptosis of cancer cells by selectively killing the cancer cells 
that expressed high levels of anti-apoptotic Bcl-2 and Bcl-xl [18-20]. 
Bcl-2 is known to be over-expressed in 70% of breast cancer cells [21], 
therefore, it is reasonable to expect antimycin A3 and its analogs to 
induce apoptosis of those cells.
In 2012, we have succeeded to synthesize novel polyhydroxylated 
18-membered analog of antimycin A3 which demonstrated strong 
anticancer activity against HeLa cells, breast MDA-MB-231 cells, and 
prostate PC-3 cells [22]. In 2015, we reported the synthesis of novel 
open-chain analog of antimycin A3 that showed anticolorectal cancer 
activity against HCT-116 cells [23]. In this research, we focused on 
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the molecular docking study of antimycin A3 analog and its aromatic 
segments (Figs. 1 and 2) which have simple opened-chain structures 
but are expected to have higher cytotoxic activities than the original 
antimycin A3 (Fig. 3).
Many researchers have accomplished the molecular docking study 
of active compounds with protein or drug target. Agarwal et al. in 
2014 conducted in silico molecular docking analysis to access the 
antibacterial effect of thiazides on peptide deformylases [24]. In 2016, 
Dirar et al. reported molecular docking study of three phytochemicals 
isolated from Tarchonanthus camphoratus L. [25]. As our contribution 
to develop in silico molecular docking as a screening method, we 
reported in silico screening of antimycin A3 analogs as inhibitors of anti-
apoptotic Bcl-2 of breast cancer in 2014 [26], and as caspases inhibitors 
of apoptosis in colorectal cancer in 2016 [27]. Recently, in 2017, we 
carried out the screening of 15 gallic acid derivatives as inhibitors of 
malarial dihydrofolate reductase by in silico docking [28].
In this work, we designed the structure of antimycin A3 analogs by 
opening the nine-membered dilactone ring system of antimycin A3 and 
introducing the hydroxyl groups on the side chain of the ester group 
(Table 1), as well as replacing 3-formamidosalicylyl moiety in antimycin 
A3 with 3-formamido-2-methoxybenzoyl moiety in the analogs (Table 2). 
Tzung et al. reported 2-methoxy-antimycin A3 which was synthesized 
by methylation of the hydroxyl group on 3-formamidosalicylyl moiety 
of antimycin A3, is inactive as an inhibitor of cellular respiration but 
still retain its cytotoxicity against cancer cells that expressed high 
levels of anti-apoptotic Bcl-2 and Bcl-xl [29]. Thus, the introduction of 
3-formamido-2-methoxybenzoyl moiety and a hydroxyl group on the 
side chain of the ester group in the analogs are expected to significantly 
improve its cytotoxic activities as well as its selectivity as an apoptotic 
trigger in breast cancer cells compared to that of the original antimycin A3.
Fig. 1: Designed structure of antimycin A3 analogs
Fig. 2: Designed structure of aromatic segments 
Fig. 3: Structure of antimycin A3 
Table 1: R1‑R3 modification of antimycin A3 analogues
Compound R1 R2 R3
Amide 3 −CH2-C6H5 H
Amide 4 −CH2-C6H5 H
Amide 5 −CH2-C6H5 H CH=CH2
Amide 6 −CH3 H CH=CH2
Amide 9 −CH3 −CH3 CH=CH2
Analogue 1 H H
Analogue 2 H H
Analogue 7 −CH3 H
Analogue 8 −CH3 H
Analogue 10 −CH3 −CH3
Analogue 11 −CH3 −CH3
Table 2: R4‑R5 modification of aromatic segments 
Compound R4 R5
Segment 13 H H
Segment 14 H CH3
Segment 15 CH3 CH3
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METHODS
Design and preparation of antimycin A3 analogs and its aromatic 
segments compounds
Antimycin A3 analogs and its aromatic segments compound modeled 
into three-dimensional (3D) structures. The modeling was performed 
using MarvinSketch and openbabel for converting the type of file from.
mol into.pdb.
Preparation 3D structure of proteins
The 3D structure of protein Bcl-xl and MCL-1 was downloaded from 
Protein Data Bank (PDB) (http://www.rcsb.org/pdb/home/home.do). 
From PDB, 3ZLN (PDB ID for Bcl-xl) was selected with the resolution 
2.29 Å and 181 aa length. PDB ID 5IEZ for protein Mcl-1 was selected 
with the resolution 2.6 Å and 159 aa length.
Preparation 3D structure of proteins Bcl-xl and Mcl-1 (PDB ID: 3ZLN and 
5IEZ) using the AutoDock 4.2.3 software that runs on a single computer 
Intel® CoreTM i5-2450M with processor 2.50 Ghz. Polar hydrogens and 
Gasteiger charge were added.
In silico docking receptor on target antimycin A3 analogs
The process of in silico docking begins with file preparation using a 
docking program in AutoDock 4.2.3 software. Antimycin A3 analogs 
and its aromatic segments (then called ligand) and the receptor, polar 
hydrogen, and Gasteiger charge were added, and nonpolar hydrogen 
was merged. Ligand and macromolecule were saved in.pdbqt format 
file for later use in the preparation parameters. Grid box used for 
optimization and validation docking method was 40 × 40 × 40, 50 × 50 × 
50, and 60 × 60 × 60 grid points with a grid spacing of 0.375 Ǻ. Docking 
calculations executed by the algorithm parameters Lamarckian genetic 
algorithm with a population size of 150, 10,000.000 energy evaluation 
and repetition (engine runs) as much as 10 times. These parameters 
were saved in a format.dlg as a file to be used to carry out the process of 
docking. Docking process was performed using AutoDock 4.2.3 software.
Analysis of in silico docking
The results of in silico docking calculations can be seen in output.dlg 
format. Determination of ligand-receptor conformation results of 
docking is done by selecting ligand conformations which have lowest 
binding affinity energy of the group (cluster) with the largest number of 
population with a limit of a standard deviation of 1.5 Å. Energy binding 
and inhibition constants (ICs) docking results can be seen in output 
docking format.dlg. The amino acid interaction was determined using 
Ligplus software. Visualization of docking pose in 3D was analyzed 
using PyMOL software.
RESULTS AND DISCUSSION
Molecular docking for in silico study
All of the designed compounds were acceptable as drug candidate 
based on Lipinski rule’s of five (molecular weight ≤500, hydrogen bond 
donor ≤5, hydrogen bond acceptor ≤10, and LogP <5). 
Validation of Bcl‑xl docking method
The optimum grid box size for Bcl-xl (PDB ID 3ZLN) is 40 × 40 × 40 
points with the grid center is −19.38, −12.437, and 13.099 (Table 3). 
H0Y as cocrystal ligand was re-docked and the result of docking score is 
−14.81 Kcal/mol with RMSD 0.60.
H0Y as cocrystal ligand has interaction with 16 amino acids on 
binding site of receptor target (Bcl-xl) and has four hydrogen bonds 
with Arg139 (2.97 Å), Asn136 (2.86 Å), Ser106 (2.76 Å), and Leu108 
(2.99 Å) (Fig. 4).
Docking analysis for Bcl‑xl
Based on docking results for antimycin A3 have docking score −7.74 
Kcal/mol (Table 4), Antimycin A3 has four hydrogen bonds with 
Ser106 (2.61 Å; 2.99 Å; 2.96 Å and 2.76 Å) and 13 amino acids 
interaction with binding site of Bcl-xl (Fig. 5). This hydrogen bond 
can improve the stability amino acid interaction between ligand and 
receptor.
Amide 5 and aromatic segment 14 have the best docking score with 
value of −9.20 and −6.04 Kcal/mol, respectively (Table 4). Amide 5 has 
three hydrogen bonds with Ser106 (2.56 Å) and Arg102 (2.67 Å and 
2.90 Å) (Fig. 6). Amide 6 and analog 2 have the same docking score 
with value of -8.45 Kcal/mol (Table 4), it showed that modification of 
R1 (-CH2-C6H5) into another group (CH3 and H) resulted in decreasing 
of activity. Amide 3, amide 4, and amide 5 have the same R1 (-CH2-
Fig. 4: Amino acid interaction between H0Y (cocrystal ligand) and 
Bcl‑xl (PDB ID 3ZLN)
Fig. 5: Amino acid interaction between antimycin A3 and Bcl‑xl 
(PDB ID 3ZLN)
Table 3: Optimization grid box for Bcl‑xl docking method
Grid box Grid center Docking score RMSD
40 x 50 x 40 X=−19.38 −14.81 0.60
50 x 50 x 50 Y=−12.437 −14.51 0.61
60 x 60 x 60 z=13.099 −14.81 0.60
Table 4: Optimization grid box for Mcl‑1 docking method
Grid box Grid center Docking score RMSD
40 x 50 x 40 X=3.926 −9.78 1.63
50 x 50 x 50 Y=17.33 −9.86 1.55
60 x 60 x 60 z=65.765 −10.64 1.01
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C6H5), but they are different in the R3 side chain. Compared to amide 
3 and 4, amide 5 which has R3 (CH=CH2) shows higher affinity. It can 
be concluded that the presence of R3 (CH=CH2) in amide 5 is necessary 
to increase its affinity against Bcl-xl. Amide 9 and analog 10 have the 
same methyl (CH3) group in R1 and R2, but different in R3 side chain. 
Amide 9 with (CH=CH2) group as R3 side chain has docking score of 
−8.06 Kcal/mol, whereas analog 10 with the phenolic group as R3 side 
chain has docking score of −6.85 Kcal/mol. it revealed the presence of 
more hydrophobic R3 side chain will increase the activity (Table 4).
Aromatic segment 14 with (H) as R4 and (CH3) as R5, has the best 
docking score compared to segment 13 and segment 15. Based on all 
segments docking score, we can analyze that the differences are not 
significant when R4 and R5 are H, CH3 or combination of them. Segment 
14 has two hydrogen bonds with Ser106 (3.03 Å) and Leu108 (2.89 Å) 
(Fig. 7).
Validation of Mcl‑1 docking method
The optimum grid box size for Mcl-1 (PDB ID 5IEZ) is 60 × 60 × 60 points 
with the grid center is 3.926, 17.33, and 65.765 (Table 5). 6AL as cocrystal 
ligand was re-docked and the result of docking score is −10.64 Kcal/mol 
with RMSD 1.01. 6AL as cocrystal ligand has interaction with 15 amino 
acids on binding site of receptor target (Mcl-1) (Fig. 8).
Docking analysis for Mcl‑1
Based on docking results, antimycin A3 with the docking score of −7.60 
Kcal/mol, have 14 amino acids interaction with binding site of Mcl-1 
(Fig. 9). Whereas, amide 5 with docking score of −7.05 (Table 4), has one 
hydrogen bond with Met250 (2.78 Å) and 14 amino acids interaction 
(Fig. 10). Segment 15 with docking score of −4.93 Kcal/mol has one 
hydrogen bond with Arg263 (3.24 Å) and 7 amino acids interaction 
with binding site of Mcl-1 (Fig. 11).
Amide 3, amide 4, and amide 5 have the same groups on R1 (-CH2-C6H5) 
and R2 (H), but different in R3 side chain. Amide 5 the replacement 
for R3 position will make an impact for activity (increase or decrease). 
Amide 5 with (CH=CH2) group as R3 showed the best interaction, this 
group is more hydrophobic than alkyl-diol group in amide 3 and amide 
4, it revealed that (CH=CH2) group could be strengthen the interaction 
of amide 5 with target receptors Mcl-1.
Amide 9 and analog 11 have the same docking score (−6.81 Kcal/mol) 
(Table 4), which they have the same R1 and R2 (CH3), the replacement 
on R3 positions with (CH=CH2) and phenolic groups are not significantly 
changing the activity.
Segment 15 has the best docking score compared to segment 13 and 
14, with R4 (CH3) and R5 (CH3). Based on all segments docking score, 
we can analyze that methyl groups on R4 and R5 or one of them, can 
increase the affinity between ligand and receptor.
Fig. 6: Amino acid interaction between amide 5 and Bcl‑xl (PDB 
ID 3ZLN)
Fig. 7: Amino acid interaction between segment 14 and Bcl‑xl 
(PDB ID 3ZLN)
Fig. 8: Amino acid interaction between 6AL (cocrystal ligand) and 
Mcl‑1 (PDB ID 5IEZ)
Table 5: Docking score and inhibition constant (IC) Antimycin 










Amide 3 −8.37 0.733 −6.66 13.04
Amide 4 −7.89 1.64 −4.96 233.23
Amide 5 −9.20 0.181 −7.05 6.81
Amide 6 −8.45 0.640 −6.20 28.33
Amide 9 −8.06 1.24 −6.81 10.27
Analogue 1 −7.94 1.51 −4.18 862.18
Analogue 2 −8.45 0.638 −4.15 906.84
Analogue 7 −7.04 6.87 −4.88 264.99
Analogue 8 −6.18 29.29 −5.31 128.92
Analogue 10 −6.85 9.57 −5.33 123.83
Analogue 11 −6.38 21.12 −6.81 10.2
Segment 13 −5.88 49.37 −4.57 449.61
Segment 14 −6.04 37.63 −4.78 311.71
Segment 15 −5.84 52.77 −4.93 242.68
Antimycin A3 −7.74 2.14 −7.60 2.67
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Table 5. Docking scoreBased on docking results on Table 4, IC was 
analyzed. For Bcl-xl, amide 5 and segment 14 have a good IC value, 
0.181 and 37.63 μM, respectively. For Mcl-1, amide 5 and segment 15 
have a good IC value of 6.81 and 242.68 μM, respectively. Antimycin A3 
has IC value of 2.14 μM on Bcl-xl and 2.67 μM on Mcl-1.
Fig. 9: Amino acid interaction between antimycin A3 and Mcl‑1 
(PDB ID 5IEZ)
Fig. 10: Amino acid interaction between amide 5 and Mcl‑1 (PDB 
ID 5IEZ)
Fig. 11: Amino acid interaction between segment 15 and Mcl‑1 
(PDB ID 5IEZ)
Furthermore, a combination of amide 5 and segment 14 and 
combination of amide 5 and segment 15 become a potential for Bcl-xl 
and Mcl-1 inhibitors.
CONCLUSION
Benzyl groups on R1 position and (CH=CH2) on R3 position in amide 5 
have an important role for its inhibitory activity on receptor Bcl-xl and 
Mcl-1. Methyl groups on R4 and R5 position in segment 14 and segment 
15 have an important role in increasing ligand affinity against Bcl-xl and 
Mcl-1 receptor. Our results clearly demonstrate that amide 5, segment 
14, and segment 15 of antimycin A3 analogs should be continued to 
in vitro assay as a promising candidate for the new anti-apoptosis agents.
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